Pilot Data on Telmisartan Short-term Effects on Glucose Metabolism in the Olfactory Tract in Alzheimer's Disease

Overview

Journal Brain Behav

Specialty Psychology

Date 2012 Mar 9

PMID 22399085

Citations 5

Authors

Etsuko Imabayashi

Hiroshi Matsuda

Kimiko Yoshimaru

Ichiei Kuji

Akira Seto

Yasumasa Shimano

Kimiteru Ito

Daisuke Kikuta

Tomokazu Shimazu

Nobuo Araki

Affiliations

Soon will be listed here.

Abstract

The possible effect of antihypertensive therapy on Alzheimer's disease (AD) has been studied, and angiotensin II receptor blockers (ARBs) have been suggested to exert an effect on cognitive decline. The purpose of this study is to clarify the functional effects of telmisartan, a long-acting ARB, on AD brain using prospective longitudinal (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) studies. For this purpose, brain glucose metabolism of four hypertensive patients with AD was examined with FDG-PET before and after administration of telmisartan. Studied subjects underwent three FDG-PET studies at intervals of 12 weeks. Antihypertensive treatment except for telmisartan was started after the first FDG-PET and continued for 24 weeks. Then 40-80 mg of telmisartan was added after the second FDG-PET and continued for 12 weeks.Glucose metabolism was significantly decreased during the first 12 weeks without telmisartan use at an area (-10, 21, -22, x, y, z; Z = 3.56) caudal to the left rectal gyrus and the olfactory sulcus corresponding to the left olfactory tract. In contrast, the introduction of telmisartan during the following 12 weeks preserved glucose metabolism at areas (5, 19, -20, x, y, z; Z = 3.09; 6, 19, -22, x, y, z; Z = 2.88) caudal to the bilateral rectal gyri and olfactory sulci corresponding to the bilateral olfactory tracts. No areas showed decreased glucose metabolism after the introduction of telmisartan. In AD, amyloid-β deposition is observed in the anterior olfactory nucleus (AON) of the olfactory tract. Glucose metabolism in AON may be progressively decreased and preserved by telmisartan.

Citing Articles

Therapeutic Implications of Renin-Angiotensin System Modulators in Alzheimer's Dementia.

Ababei D, Bild V, Macadan I, Vasincu A, Rusu R, Blaj M Pharmaceutics. 2023; 15(9).

PMID: 37765259 PMC: 10538010. DOI: 10.3390/pharmaceutics15092290.

Temporal Changes in Cortical and Hippocampal Expression of Genes Important for Brain Glucose Metabolism Following Controlled Cortical Impact Injury in Mice.

Zhou J, Burns M, Huynh L, Villapol S, Taub D, Saavedra J Front Endocrinol (Lausanne). 2017; 8:231.

PMID: 28955302 PMC: 5601958. DOI: 10.3389/fendo.2017.00231.

Evidence to Consider Angiotensin II Receptor Blockers for the Treatment of Early Alzheimer's Disease.

Saavedra J Cell Mol Neurobiol. 2016; 36(2):259-79.

PMID: 26993513 PMC: 11482317. DOI: 10.1007/s10571-015-0327-y.

Neurostatistical imaging for diagnosing dementia: translational approach from laboratory neuroscience to clinical routine.

Imabayashi E, Inoue T Neurosci Bull. 2014; 30(5):755-64.

PMID: 25193518 PMC: 5562589. DOI: 10.1007/s12264-014-1464-x.

Preventing vascular effects on brain injury and cognition late in life: knowns and unknowns.

Carmichael O Neuropsychol Rev. 2014; 24(3):371-87.

PMID: 25085314 PMC: 4169073. DOI: 10.1007/s11065-014-9264-7.

References

Luna-Medina R, Cortes-Canteli M, Alonso M, Santos A, Martinez A, Perez-Castillo A . Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. J Biol Chem. 2005; 280(22):21453-62. DOI: 10.1074/jbc.M414390200. View

Pearson R, Esiri M, Hiorns R, Wilcock G, Powell T . Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer disease. Proc Natl Acad Sci U S A. 1985; 82(13):4531-4. PMC: 391136. DOI: 10.1073/pnas.82.13.4531. View

Saito T, Iwata N, Tsubuki S, Takaki Y, Takano J, Huang S . Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. Nat Med. 2005; 11(4):434-9. DOI: 10.1038/nm1206. View

Braak H, Braak E . Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82(4):239-59. DOI: 10.1007/BF00308809. View

Brunjes P, Kenerson M . The anterior olfactory nucleus: quantitative study of dendritic morphology. J Comp Neurol. 2010; 518(9):1603-16. PMC: 3546507. DOI: 10.1002/cne.22293. View

Djordjevic J, Jones-Gotman M, De Sousa K, Chertkow H . Olfaction in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging. 2007; 29(5):693-706. DOI: 10.1016/j.neurobiolaging.2006.11.014. View

Kovacs T, Cairns N, Lantos P . beta-amyloid deposition and neurofibrillary tangle formation in the olfactory bulb in ageing and Alzheimer's disease. Neuropathol Appl Neurobiol. 2000; 25(6):481-91. DOI: 10.1046/j.1365-2990.1999.00208.x. View

Lerner A, Bagic A . Olfactory pathogenesis of idiopathic Parkinson disease revisited. Mov Disord. 2008; 23(8):1076-84. DOI: 10.1002/mds.22066. View

Friston K, Frith C, Liddle P, Frackowiak R . Comparing functional (PET) images: the assessment of significant change. J Cereb Blood Flow Metab. 1991; 11(4):690-9. DOI: 10.1038/jcbfm.1991.122. View

10.

Morales-Garcia J, Luna-Medina R, Alfaro-Cervello C, Cortes-Canteli M, Santos A, Garcia-Verdugo J . Peroxisome proliferator-activated receptor γ ligands regulate neural stem cell proliferation and differentiation in vitro and in vivo. Glia. 2010; 59(2):293-307. DOI: 10.1002/glia.21101. View

11.

Iadecola C, Nedergaard M . Glial regulation of the cerebral microvasculature. Nat Neurosci. 2007; 10(11):1369-76. DOI: 10.1038/nn2003. View

12.

Gard P . The role of angiotensin II in cognition and behaviour. Eur J Pharmacol. 2002; 438(1-2):1-14. DOI: 10.1016/s0014-2999(02)01283-9. View

13.

Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P . Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A. 2006; 103(2):443-8. PMC: 1326151. DOI: 10.1073/pnas.0503839103. View

14.

Saiz-Sanchez D, Ubeda-Banon I, de la Rosa-Prieto C, Argandona-Palacios L, Garcia-Munozguren S, Insausti R . Somatostatin, tau, and beta-amyloid within the anterior olfactory nucleus in Alzheimer disease. Exp Neurol. 2009; 223(2):347-50. DOI: 10.1016/j.expneurol.2009.06.010. View

15.

Camacho I, Serneels L, Spittaels K, Merchiers P, Dominguez D, De Strooper B . Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J Neurosci. 2004; 24(48):10908-17. PMC: 6730204. DOI: 10.1523/JNEUROSCI.3987-04.2004. View

16.

Kehoe P, Wilcock G . Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?. Lancet Neurol. 2007; 6(4):373-8. DOI: 10.1016/S1474-4422(07)70077-7. View

17.

Sakai Y, Kumano H, Nishikawa M, Sakano Y, Kaiya H, Imabayashi E . Changes in cerebral glucose utilization in patients with panic disorder treated with cognitive-behavioral therapy. Neuroimage. 2006; 33(1):218-26. DOI: 10.1016/j.neuroimage.2006.06.017. View

18.

Mogi M, Li J, Tsukuda K, Iwanami J, Min L, Sakata A . Telmisartan prevented cognitive decline partly due to PPAR-gamma activation. Biochem Biophys Res Commun. 2008; 375(3):446-9. DOI: 10.1016/j.bbrc.2008.08.032. View

19.

Price J, DAVIS P, Morris J, White D . The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging. 1991; 12(4):295-312. DOI: 10.1016/0197-4580(91)90006-6. View

20.

Gard P . Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression. Expert Opin Ther Targets. 2004; 8(1):7-14. DOI: 10.1517/14728222.8.1.7. View